Literature DB >> 19937655

High-resolution crystal structure of human Mapkap kinase 3 in complex with a high affinity ligand.

Robert Cheng1, Brunella Felicetti, Shilpa Palan, Ian Toogood-Johnson, Christoph Scheich, John Barker, Mark Whittaker, Thomas Hesterkamp.   

Abstract

The Mapkap kinases 2 and 3 (MK2 and MK3) have been implicated in intracellular signaling pathways leading to the production of the pro-inflammatory cytokine tumor necrosis factor alpha. MK2 has been pursued by the biopharmaceutical industry for many years for the development of a small molecule anti-inflammatory treatment and drug-like inhibitors have been described. The development of some of these compounds, however, has been slowed by the absence of a high-resolution crystal structure of MK2. Herein we present a high-resolution (1.9 A) crystal structure of the highly homologous MK3 in complex with a pharmaceutical lead compound. While all of the canonical features of Ser/Thr kinases in general and MK2 in particular are recapitulated in MK3, the detailed analysis of the binding interaction of the drug-like ligand within the adenine binding pocket allows relevant conclusions to be drawn for the further design of potent and selective drug candidates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19937655      PMCID: PMC2817852          DOI: 10.1002/pro.294

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  16 in total

1.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

Review 2.  MK2: a novel molecular target for anti-inflammatory therapy.

Authors:  Senthil Duraisamy; Malini Bajpai; Usha Bughani; Sunanda G Dastidar; Abhijit Ray; Puneet Chopra
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

3.  Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme.

Authors:  Kathryn W Underwood; Kevin D Parris; Elizabeth Federico; Lidia Mosyak; Robert M Czerwinski; Tania Shane; Meggin Taylor; Kristine Svenson; Yan Liu; Chu-Lai Hsiao; Scott Wolfrom; Michelle Maguire; Karl Malakian; Jean-Baptiste Telliez; Lih-Ling Lin; Ronald W Kriz; Jasbir Seehra; William S Somers; Mark L Stahl
Journal:  Structure       Date:  2003-06       Impact factor: 5.006

Review 4.  MK2 and MK3--a pair of isoenzymes?

Authors:  Natalia Ronkina; Alexey Kotlyarov; Matthias Gaestel
Journal:  Front Biosci       Date:  2008-05-01

5.  The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK.

Authors:  N Ronkina; A Kotlyarov; O Dittrich-Breiholz; M Kracht; E Hitti; K Milarski; R Askew; S Marusic; L-L Lin; M Gaestel; J-B Telliez
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis.

Authors:  Martin Hegen; Matthias Gaestel; Cheryl L Nickerson-Nutter; Lih-Ling Lin; Jean-Baptiste Telliez
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

7.  Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

Authors:  David R Anderson; Marvin J Meyers; William F Vernier; Matthew W Mahoney; Ravi G Kurumbail; Nicole Caspers; Gennadiy I Poda; John F Schindler; David B Reitz; Robert J Mourey
Journal:  J Med Chem       Date:  2007-05-05       Impact factor: 7.446

Review 8.  Protein kinases as small molecule inhibitor targets in inflammation.

Authors:  M Gaestel; A Mengel; U Bothe; K Asadullah
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study.

Authors:  Maria A Argiriadi; Silvino Sousa; David Banach; Douglas Marcotte; Tao Xiang; Medha J Tomlinson; Megan Demers; Christopher Harris; Silvia Kwak; Jennifer Hardman; Margaret Pietras; Lisa Quinn; Jennifer DiMauro; Baofu Ni; John Mankovich; David W Borhani; Robert V Talanian; Ramkrishna Sadhukhan
Journal:  BMC Struct Biol       Date:  2009-03-18

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  5 in total

1.  The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor.

Authors:  Sergiy Kostenko; Mahmud Tareq Hassan Khan; Ingebrigt Sylte; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

2.  Comparative molecular dynamics simulations of mitogen-activated protein kinase-activated protein kinase 5.

Authors:  Inger Lindin; Yimingjiang Wuxiuer; Aina Westrheim Ravna; Ugo Moens; Ingebrigt Sylte
Journal:  Int J Mol Sci       Date:  2014-03-19       Impact factor: 5.923

Review 3.  MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression.

Authors:  Sourabh Soni; Prince Anand; Yogendra S Padwad
Journal:  J Exp Clin Cancer Res       Date:  2019-03-08

4.  Chrysophanol, Physcion, Hesperidin and Curcumin Modulate the Gene Expression of Pro-Inflammatory Mediators Induced by LPS in HepG2: In Silico and Molecular Studies.

Authors:  Nabil Mohamed Selim; Abdullah Abdurrahman Elgazar; Nabil Mohie Abdel-Hamid; Mohammed Rizk Abu El-Magd; Aziz Yasri; Hala Mohamed El Hefnawy; Mansour Sobeh
Journal:  Antioxidants (Basel)       Date:  2019-09-03

5.  Homology modeling and ligand docking of Mitogen-activated protein kinase-activated protein kinase 5 (MK5).

Authors:  Inger Lindin; Yimingjiang Wuxiuer; Irina Kufareva; Ruben Abagyan; Ugo Moens; Ingebrigt Sylte; Aina Westrheim Ravna
Journal:  Theor Biol Med Model       Date:  2013-09-14       Impact factor: 2.432

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.